Maze Therapeutics Soars 11.68% on Wedbush's Outperform Rating

On July 10, 2025, Maze Therapeutics surged 11.68% in pre-market trading, marking a significant rise in its stock price.

On July 8, 2025, Wedbush analyst Laura Chico initiated coverage on Maze Therapeutics, assigning an Outperform rating and setting a 12-month price target of $17. This move underscores the analyst's confidence in the company's potential, particularly highlighting the Compass discovery platform as a key driver of future growth.

This positive analyst coverage comes on the heels of Maze Therapeutics' successful initial public offering (IPO) on January 31, 2025, where the company raised $140 million by issuing 8,750,000 shares. The IPO not only provided the company with substantial capital but also garnered significant investor interest, setting a strong foundation for its future endeavors.